Re-irradiation of Recurrent Esophageal Cancer After Primary Definitive Radiotherapy

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2013 Jan 25

PMID 23346537

Citations 23

Authors

Young Suk Kim

Chang Geol Lee

Kyung Hwan Kim

Taehyung Kim

Joohwan Lee

Yona Cho

Woong Sub Koom

Affiliations

Soon will be listed here.

Abstract

Purpose: For recurrent esophageal cancer after primary definitive radiotherapy, no general treatment guidelines are available. We evaluated the toxicities and clinical outcomes of re-irradiation (re-RT) for recurrent esophageal cancer.

Materials And Methods: We analyzed 10 patients with recurrent esophageal cancer treated with re-RT after primary definitive radiotherapy. The median time interval between primary radiotherapy and re-RT was 15.6 months (range, 4.8 to 36.4 months). The total dose of primary radiotherapy was a median of 50.4 Gy (range, 50.4 to 63.0 Gy). The total dose of re-RT was a median of 46.5 Gy (range, 44.0 to 50.4 Gy).

Results: The median follow-up period was 4.9 months (range, 2.6 to 11.4 months). The tumor response at 3 months after the end of re-RT was complete response (n = 2), partial response (n = 1), stable disease (n = 2), and progressive disease (n = 5). Grade 5 tracheoesophageal fistula developed in three patients. The time interval between primary radiotherapy and re-RT was less than 12 months in two of these three patients. Late toxicities included grade 1 dysphagia (n = 1).

Conclusion: Re-RT of recurrent esophageal cancer after primary radiotherapy can cause severe toxicity.

Citing Articles

Treatment Strategies for Locoregional Recurrence in Esophageal Squamous-Cell Carcinoma: An Updated Review.

Mitamura A, Tsujinaka S, Nakano T, Sawada K, Shibata C Cancers (Basel). 2024; 16(14).

PMID: 39061179 PMC: 11274925. DOI: 10.3390/cancers16142539.

Reirradiation With Proton Therapy for Recurrent Malignancies of the Esophagus and Gastroesophageal Junction: Results of the Proton Collaborative Group Multi-Institutional Prospective Registry Trial.

Hotca A, Sindhu K, Lehrer E, Hartsell W, Vargas C, Tsai H Adv Radiat Oncol. 2024; 9(5):101459.

PMID: 38596455 PMC: 11002543. DOI: 10.1016/j.adro.2024.101459.

Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis.

Lan K, Chen J Radiat Oncol. 2022; 17(1):61.

PMID: 35346285 PMC: 8962014. DOI: 10.1186/s13014-022-02019-0.

Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site.

Wang X, Hu B, Chen J, Xie F, Han D, Zhao Q BMC Cancer. 2022; 22(1):207.

PMID: 35209855 PMC: 8876373. DOI: 10.1186/s12885-022-09319-4.

Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.

Gabrys D, Kulik R, Namysl-Kaletka A Br J Radiol. 2021; 95(1132):20201292.

PMID: 34826226 PMC: 9153724. DOI: 10.1259/bjr.20201292.

References

Teli M, Mushood G, Zargar S, Andrabi W . Comparative evaluation between re-irradiation and demand endoscopic dilatation vs endoscopic dilatation alone in patients with recurrent/reactivated residual in-field esophageal malignancies. J Cancer Res Ther. 2008; 4(3):121-5. DOI: 10.4103/0973-1482.43140. View

Yamaguchi S, Ohguri T, Imada H, Yahara K, Moon S, Higure A . Multimodal approaches including three-dimensional conformal re-irradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res. 2011; 52(6):812-20. DOI: 10.1269/jrr.11066. View

Russo J, Rosen L . TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: a case report. Tumori. 2011; 97(3):406-10. DOI: 10.1177/030089161109700325. View

Araujo C, Souhami L, Gil R, Carvalho R, Garcia J, Froimtchuk M . A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer. 1991; 67(9):2258-61. DOI: 10.1002/1097-0142(19910501)67:9<2258::aid-cncr2820670908>3.0.co;2-g. View

Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K . Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008; 40(9):717-21. DOI: 10.1055/s-2008-1077480. View

Morita M, Kumashiro R, Hisamatsu Y, Nakanishi R, Egashira A, Saeki H . Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol. 2011; 46(11):1284-91. DOI: 10.1007/s00535-011-0448-0. View

Sharma V, Mahantshetty U, Dinshaw K, Deshpande R, Sharma S . Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2002; 52(2):310-5. DOI: 10.1016/s0360-3016(01)01822-3. View

Shioyama Y, Nakamura K, Ohga S, Nomoto S, Sasaki T, Yamaguchi T . Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2008; 37(12):918-23. DOI: 10.1093/jjco/hym138. View

Tachimori Y . Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg. 2009; 57(2):71-8. DOI: 10.1007/s11748-008-0337-5. View

10.

Hattori S, Muto M, Ohtsu A, Boku N, Manabe T, Doi T . EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc. 2003; 58(1):65-70. DOI: 10.1067/mge.2003.306. View

11.

Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H . Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012; 188(2):136-42. DOI: 10.1007/s00066-011-0023-x. View

12.

Harms W, Krempien R, Grehn C, Berns C, Hensley F, Debus J . Daytime pulsed dose rate brachytherapy as a new treatment option for previously irradiated patients with recurrent oesophageal cancer. Br J Radiol. 2005; 78(927):236-41. DOI: 10.1259/bjr/51982166. View

13.

Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S . Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus. 2006; 19(2):73-7. DOI: 10.1111/j.1442-2050.2006.00543.x. View

14.

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

15.

Nonoshita T, Sasaki T, Hirata H, Toh Y, Shioyama Y, Nakamura K . High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiat Med. 2007; 25(8):373-7. DOI: 10.1007/s11604-007-0152-4. View